Opioid receptor ligands and methods for their preparation
申请人:Prisinzano Thomas
公开号:US20060058264A1
公开(公告)日:2006-03-16
The invention provides novel compounds of formula I:
that are opioid receptor ligands. The invention also provides pharmaceutical compositions comprising such compounds as well as methods for treating diseases associated with opioid receptor function by administering such compounds to a mammal in need of treatment. The invention also provides an improved method for isolating intermediate materials useful for obtaining compounds of formula I.
Herkinorin Analogues with Differential β-Arrestin-2 Interactions
作者:Kevin Tidgewell、Chad E. Groer、Wayne W. Harding、Anthony Lozama、Matthew Schmidt、Alfred Marquam、Jessica Hiemstra、John S. Partilla、Christina M. Dersch、Richard B. Rothman、Laura M. Bohn、Thomas E. Prisinzano
DOI:10.1021/jm701162g
日期:2008.4.1
Salvinorin A is a psychoactive natural product that has been found to be a potent and selective kappa opioid receptor agonist in vitro and in vivo. The activity of salvinorin A is unusual compared to other opioids such as morphine in that it mediates potent kappa opioid receptor signaling yet leads to less receptor downregulation than observed with other kappa agonists. Our initial chemical modifications of salvinorin A have yielded one analogue, herkinorin (1c), with high affinity at the mu OR. We recently reported that 1c does not promote the recruitment of beta-arrestin-2 to the mu OR or receptor internalization. Here we describe three new derivatives of 1c (3c, 3f, and 3i) with similar properties and one, benzamide 7b, that promotes recruitment of beta-arrestin-2 to the mu OR and receptor internalization. When the important role mu opioid receptor regulation plays in determining physiological responsiveness to opioid narcotics is considered,mu opioids derived from salvinorin A may offer a unique template for the development of functionally selective mu opioid receptor-ligands with the ability to produce analgesia while limiting adverse side effects.